Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab in Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5
NCT07631208Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2026
- Primary completion
- Jan 2027
01
Overview
Phase 2, open-label, single-arm trial of teclistamab in interstitial lung disease (ILD), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Transplant-free survival at 90 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
teclistamab
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT07631208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07631208.